免疫抑制药物管理对袖状胃切除术后短期并发症的影响
该单中心回顾性研究纳入2008至2022年75例接受袖状胃切除术的慢性免疫抑制治疗患者,比较围术期暂停与继续用药的短期结局。暂停组早期并发症(5% vs 20%,p=0.031)及30天再入院、再手术均更低,体重结局无差异。提示临床可行时个体化暂停免疫抑制可能获益。
要点
- 暂停免疫抑制组早期并发症显著低于继续用药组(5% vs 20%,p=0.031)。
- 暂停组无30天再入院或再手术,继续组分别为16.4%和5.5%。
- 两组3个月和6个月总体重减轻百分比无显著差异。
核心结论
- 袖状胃切除术患者围术期暂时停用慢性免疫抑制治疗与更低的早期并发症率和更好的短期结局相关。
- 研究结果强调个体化围术期免疫抑制管理的重要性,并提示临床可行时暂停用药可能获益。
研究设计与样本
- 单中心回顾性研究,纳入2008至2022年接受袖状胃切除术的75例慢性免疫抑制治疗患者。
- 按围术期管理分为暂停组20例(26.7%)和继续组55例(73.3%),分析人口学、用药指征、手术细节及短期结局。
主要发现
- 继续用药组最常见的免疫抑制指征为器官移植(61.4%),暂停组最常见为类风湿关节炎(50%)。
- 早期并发症(≤30天)在继续用药组显著更高(20% vs 5%,p=0.031),最常见为出血(7例),其次为伤口感染(4例)。
- 暂停组仅发生1例并发症(伤口感染),无30天再入院或再手术;继续组30天再入院率16.4%、再手术率5.5%。
- 两组3个月和6个月总体重减轻百分比无显著差异。
临床怎么用
- 对接受袖状胃切除术的慢性免疫抑制治疗患者,围术期可考虑在临床可行时个体化暂停免疫抑制以降低早期并发症风险。
- 暂停决策需权衡基础疾病活动风险,尤其器官移植患者继续用药比例较高,应结合指征个体化处理。
局限性
- 单中心回顾性设计,样本量较小(75例),暂停组仅20例,可能存在选择偏倚和混杂。
- 原文未报告长期结局及免疫抑制暂停相关基础疾病复发数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sleeve gastrectomy (SG) is the most performed bariatric procedure in the United States due to its favorable safety profile. However, managing patients on chronic immunosuppressive therapy (CIT) during bariatric surgery poses challenges, particularly in balancing surgical outcomes with the risks associated with CIT interruption. This study aims to compare the short-term outcomes of SG in patients who temporarily discontinued CIT versus those who continued it perioperatively. METHODS: A retrospective review was conducted of 75 patients on CIT who underwent SG at a single academic center between 2008 and 2022. Patients were categorized based on perioperative CIT management: 20 (26.7%) interrupted CIT and 55 (73.3%) continued therapy. Data on patient demographics, CIT indications, operative details, and short-term outcomes, including complications and readmissions, were analyzed. RESULTS: The most common CIT indication was organ transplantation (61.4%), predominantly in the non-interruption group, while rheumatoid arthritis was the leading indication (50%) among patients who interrupted CIT. Early complications (≤ 30 days) were significantly higher in the non-interruption group (20% vs. 5%, p = 0.031), with bleeding being the most frequent (7 cases), followed by wound infections (4 cases). In contrast, the interruption group experienced only one complication, a wound infection. Weight outcomes were similar between groups, with no significant differences in percentage of total weight loss (%TWL) at 3 or 6 months. Notably, the interruption group had no 30-day readmissions or reoperations, compared to 16.4% and 5.5%, respectively, in the non-interruption group. CONCLUSIONS: Temporary interruption of CIT in SG patients is associated with lower early complication rates and improved short-term outcomes. These findings highlight the importance of individualized perioperative CIT management and suggest potential benefits of CIT interruption when clinically feasible.
引用
- Abi Mosleh K, Bocchinfuso S, Bartosiak K, et al. Impact of immunosuppression medication management on short-term complications following sleeve gastrectomy. Surg Endosc. 2025. PMID: 40045057. doi:10.1007/s00464-025-11628-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。